Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral clearance 33% Improvement Relative Risk Usanma Koban et al. Vitamin C for COVID-19 EARLY Is early treatment with vitamin C beneficial for COVID-19? Retrospective 126 patients in Turkey (March - September 2020) No significant difference in viral clearance Usanma Koban et al., Bratislava Medical J., doi:10.4149/BLL_2022_082 Favors vitamin C Favors control
The factors affecting the prolonged PCR positivity in COVID-19 patients
Usanma Koban et al., Bratislava Medical Journal, doi:10.4149/BLL_2022_082
Usanma Koban et al., The factors affecting the prolonged PCR positivity in COVID-19 patients, Bratislava Medical Journal, doi:10.4149/BLL_2022_082
Jun 2022   Source   PDF  
  All Studies   Meta
Retrospective 126 patients in Turkey, showing no significant difference in PCR+ at day 14 with vitamin C treatment.
This is the 47th of 61 COVID-19 controlled studies for vitamin C, which collectively show efficacy with p=0.00000098. 15 studies are RCTs, which show efficacy with p=0.00013.
This study includes vitamin C and favipiravir.
risk of no viral clearance, 33.0% lower, OR 0.67, p = 0.73, treatment 31, control 95, adjusted per study, multivariable, day 14, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Usanma Koban et al., 7 Jun 2022, retrospective, Turkey, peer-reviewed, 3 authors, study period 1 March, 2020 - 30 September, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
The factors affecting the prolonged PCR positivity in COVID-19 patients
Bugu Usanma koban, Sanem Aslihan Aykan, Sinem Demir
Bratislava Medical Journal, doi:10.4149/bll_2022_082
OBJECTIVES: The aim of this study is to investigate the effects of factors such as age, gender, comorbid diseases and treatments applied on the positive duration of the PCR test in COVID-19 patients. Background: The duration of PCR positivity in COVID-19 patients varies. Studies in the literature investigating factors that may affect this duration are limited. METHODS: Between March and September 2020, individuals with two or more positive PCR results with a 14-day interval were included in the case group, and those whose PCR results turned negative within 14 days were included in the control group. The relationship between age, gender, contact environment, presence of additional disease, drugs used, smoking and alcohol consumption; type, duration and severity of COVID-19 symptoms, treatment applied for COVID-19 and duration of PCR positivity were examined. RESULTS: Among 126 participants the mean duration of PCR positivity was 23.38 days (min 6, max 52). Symptoms lasted 15-30 days in 41 patients (32.5 %) and 5 -10 days in 30 patients (23.8 %). The positivity duration varied according to age, smoking and alcohol consumption status, and body mass index. Patients with chronic disease, and who had loss of taste and smell during the disease had a longer positive stay. This period was shorter in favipiravir users. CONCLUSION: In COVID-19 infection, there are several factors that affect the PCR test to remain positive. Early-term favipiravir use may shorten this period as a modifi able factor (Tab. 3, Ref. 14). Text in PDF
Aldhaeefi, Tahir, Cote, Izzy, Khoury, Comorbidities and Age Are Associated With Persistent COVID-19 PCR Positivity, Front Cell Infect Microbiol
Bulut, Kato, Epidemiology of COVID-19, Turk J Med Sci
Carmo, Pereira-Vaz, Mota, Mendes, Morais et al., Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19, J Med Virol
Cento, Colagrossi, Nava, Lamberti, Senatore et al., Persistent positivity and fl uctuations of SARS-CoV-2 RNA in clinicallyrecovered COVID-19 patients, J Infect
Erensoy, COVID-19 Pandemisinde SARS-CoV-2 ve Mikrobiyolojik Tani Dinamikleri, MİKROBİYOLOJİ Bül
Fu, Li, Guo, He, Liu et al., Dynamics and Correlation Among Viral Positivity, Seroconversion and Disease Severity in COVID-19: A Retrospective Study, Ann Intern Med Nisan
Ikegami, Benirschke, Flanagan, Tanna, Klein et al., Persistence of SARS-COV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors, Transfusion
Li, Liu, Zhang, Xu, Dai et al., SARS-CoV-2 and viral sepsis: observations and hypotheses, Lancet Lond Engl
Liu, Yan, Wan, Xiang, Le et al., Viraldynamics in mildand severe cases of COVID-19, Lancet Infect Dis
Lu, Yin, Li, Fu, Hu et al., Clinical characteristics and factors affecting the duration of positive nucleic acid test for patients of COVID-19 in XinYu, China, J Clin Lab Anal
Rabaan, Tirupathi, Sule, Aldali, Mutair et al., Viral Dynamics and Real-Time RT-PCR CtValues Correlation with Disease Severity in COVID-19, Diagn Basel Switz
Suri, Mittal, Tiwari, Mohan, Hadda et al., CO-VID-19 Real-Time RT-PCR: Does Positivity on Follow-up RT-PCR Always Imply Infectivity?, Am J Respir Crit Care Med
Van Kampen, Van De Vijver, Fraaij, Haagmans, Lamers et al., Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19), Nat Commun
Xu, Chen, Yuan, Yi, Ding et al., Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19), Clin Infect Dis Publ Infect Dis Soc Am
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop